Eurofins-Cerep SA
PAR:ALECR
Net Margin
Eurofins-Cerep SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Eurofins-Cerep SA
PAR:ALECR
|
111m EUR |
17%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
150.2B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
140.5B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
70.8T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.1B CHF |
10%
|
|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
6.8T JPY |
-5%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.8B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD |
9%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
185.1B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24B USD |
22%
|
Eurofins-Cerep SA
Glance View
Eurofins-Cerep SA engages in providing preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 211 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Eurofins-Cerep SA's most recent financial statements, the company has Net Margin of 16.9%.
You don't have any saved screeners yet